MUC-1 CAR T-cell

MUC-1 CAR T-cell is an autologous or allogeneic adoptive cell therapy in which patient or donor-derived T cells are genetically engineered to express a chimeric antigen receptor (CAR) that specifically targets the tumor-associated antigen mucin 1 (MUC1). MUC1 is a glycoprotein overexpressed and aberrantly glycosylated in many epithelial cancers including breast cancer, colorectal cancer, esophageal adenocarcinoma, seminal vesicle cancer, and head and neck squamous cell carcinoma. The engineered CAR enables the modified T cells to recognize and kill tumor cells expressing MUC1. Some advanced versions of these therapies co-express cytokines such as IL-12 or IL-22 to enhance anti-tumor activity and persistence. Clinical trials have demonstrated safety signals and early efficacy in solid tumors; however, challenges remain due to on-target off-tumor toxicity from low-level expression of MUC1 on normal tissues[3][5]. Dual-targeting strategies with additional antigens are under investigation to improve specificity[5].

Other names

MUC-1 CAR T细胞Anti-Mucin 1 (MUC1) CAR-T cellMucin 1-targeted chimeric antigen receptor T cellMucin1-targeted chimeric antigen receptor T cellMucin-1-targeted chimeric antigen receptor T cell